TriangleNCT00002597 · OUTCOME
Disease-specific Survival Rate (10 Years)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From registration to 10 years
What was measured
Disease-specific failure is defined as death certified as due to prostate cancer (by central review), death due to complications of treatment (irrespective of malignancy status), death from unknown causes with active malignancy, or death from unknown causes with previously documented relapse (either clinical or biochemical). Survival rates were estimated by means of cumulative incidence functions.
Analysis population: All eligible patients.
Groups in this outcome
Hormone Therapy + Radiation Therapy
Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.
Radiation Therapy Alone
Radiation therapy alone
| Group | Source count |
|---|---|
| Hormone Therapy + Radiation Therapy | 987 |
| Radiation Therapy Alone | 992 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Hormone Therapy + Radiation Therapy | 95.7 | Not reported | 94.3 | 97.2 | Not reported |
| Radiation Therapy Alone | 92.6 | Not reported | 90.8 | 94.4 | Not reported |
Source statistical analyses
- ci Lower Limit
- 1.27
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 2.74
- estimate Comment
- Reference level = Hormone Therapy + Radiation Therapy
- group Description
- Gray's test was used to compare cumulative incidence between treatment arms (1-sided significance level of 0.025) and the Fine-Gray model was used to calculate hazard ratios.
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- p Value
- 0.001
- param Type
- Hazard Ratio (HR)
- param Value
- 1.86
- statistical Method
- Gray's test
Complete source fields
- analyses
- ci Lower Limit
- 1.27
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 2.74
- estimate Comment
- Reference level = Hormone Therapy + Radiation Therapy
- group Description
- Gray's test was used to compare cumulative incidence between treatment arms (1-sided significance level of 0.025) and the Fine-Gray model was used to calculate hazard ratios.
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- p Value
- 0.001
- param Type
- Hazard Ratio (HR)
- param Value
- 1.86
- statistical Method
- Gray's test
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 94.3
- upper Limit
- 97.2
- value
- 95.7
- group Id
- OG001
- lower Limit
- 90.8
- upper Limit
- 94.4
- value
- 92.6
- denoms
- counts
- group Id
- OG000
- value
- 987
- group Id
- OG001
- value
- 992
- units
- Participants
- description
- Disease-specific failure is defined as death certified as due to prostate cancer (by central review), death due to complications of treatment (irrespective of malignancy status), death from unknown causes with active malignancy, or death from unknown causes with previously documented relapse (either clinical or biochemical). Survival rates were estimated by means of cumulative incidence functions.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.
- id
- OG000
- title
- Hormone Therapy + Radiation Therapy
- description
- Radiation therapy alone
- id
- OG001
- title
- Radiation Therapy Alone
- param Type
- NUMBER
- population Description
- All eligible patients.
- reporting Status
- POSTED
- time Frame
- From registration to 10 years
- title
- Disease-specific Survival Rate (10 Years)
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice